Development
Ocular Therapeutix, Inc.
OCUL
$8.33
$0.030.36%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 14.80M | 15.08M | 15.19M | 13.37M | 14.08M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.80M | 15.08M | 15.19M | 13.37M | 14.08M |
| Cost of Revenue | 17.58M | 16.40M | 16.40M | 15.96M | 14.56M |
| Gross Profit | -2.78M | -1.32M | -1.21M | -2.59M | -480.00K |
| SG&A Expenses | 17.27M | 17.90M | 19.36M | 19.96M | 18.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.85M | 34.30M | 35.76M | 35.92M | 33.44M |
| Operating Income | -20.05M | -19.21M | -20.57M | -22.55M | -19.36M |
| Income Before Tax | -29.22M | -516.00K | -20.68M | -30.32M | -15.54M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -29.22M | -516.00K | -20.68M | -30.32M | -15.54M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.22M | -516.00K | -20.68M | -30.32M | -15.54M |
| EBIT | -20.05M | -19.21M | -20.57M | -22.55M | -19.36M |
| EBITDA | -19.09M | -18.32M | -19.92M | -22.07M | -18.87M |
| EPS Basic | -0.35 | -0.01 | -0.27 | -0.39 | -0.20 |
| Normalized Basic EPS | -0.22 | -0.12 | -0.17 | -0.24 | -0.13 |
| EPS Diluted | -0.35 | -0.25 | -0.27 | -0.39 | -0.24 |
| Normalized Diluted EPS | -0.22 | -0.11 | -0.17 | -0.24 | -0.12 |
| Average Basic Shares Outstanding | 84.43M | 79.37M | 78.05M | 77.39M | 77.01M |
| Average Diluted Shares Outstanding | 84.43M | 85.14M | 78.05M | 77.39M | 82.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |